NasdaqGM - Delayed Quote USD

Travere Therapeutics, Inc. (TVTX)

Compare
7.34 +0.27 (+3.82%)
At close: June 12 at 4:00 PM EDT
7.34 0.00 (0.00%)
After hours: June 12 at 5:43 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
155,724.00
145,238.00
109,460.00
131,836.00
198,321.00
--
Cost of Revenue
8,809.00
11,450.00
4,420.00
3,818.00
6,126.00
--
Gross Profit
146,915.00
133,788.00
105,040.00
128,018.00
192,195.00
--
Operating Expense
565,268.00
510,532.00
424,853.00
327,443.00
267,572.00
--
Operating Income
-418,353.00
-376,744.00
-319,813.00
-199,425.00
-75,377.00
--
Net Non Operating Interest Income Expense
12,870.00
10,434.00
-4,738.00
-17,689.00
-14,047.00
--
Other Income Expense
-9,908.00
-9,800.00
-6,604.00
231.00
-99,366.00
--
Pretax Income
-415,391.00
-376,110.00
-331,155.00
-216,883.00
-188,790.00
--
Tax Provision
336.00
223.00
313.00
409.00
-19,359.00
--
Net Income Common Stockholders
-161,129.00
-111,399.00
-278,482.00
-180,091.00
-169,431.00
--
Diluted NI Available to Com Stockholders
-161,129.00
-111,399.00
-278,482.00
-180,091.00
-169,431.00
--
Basic EPS
-1.99
-1.50
-4.37
-3.01
-3.56
--
Diluted EPS
-1.99
-1.50
-4.37
-3.01
-3.56
--
Basic Average Shares
76,508.02
74,267.42
63,758.52
59,832.29
47,539.63
--
Diluted Average Shares
76,508.02
74,267.42
63,758.52
59,832.29
47,539.63
--
Total Operating Income as Reported
-430,006.00
-388,138.00
-319,813.00
-199,425.00
-176,163.00
--
Total Expenses
574,077.00
521,982.00
429,273.00
331,261.00
273,698.00
--
Net Income from Continuing & Discontinued Operation
-161,129.00
-111,399.00
-278,482.00
-180,091.00
-169,431.00
--
Normalized Income
-408,735.20
-367,331.74
-325,481.38
-217,292.00
-78,975.57
--
Interest Income
24,154.00
21,768.00
6,276.00
1,993.00
5,003.00
--
Interest Expense
11,284.00
11,334.00
11,014.00
19,682.00
19,050.00
--
Net Interest Income
12,870.00
10,434.00
-4,738.00
-17,689.00
-14,047.00
--
EBIT
-404,107.00
-364,776.00
-320,141.00
-197,201.00
-169,740.00
--
EBITDA
-362,317.00
-326,246.00
-299,422.00
-184,455.00
-145,161.00
--
Reconciled Cost of Revenue
8,809.00
11,450.00
4,420.00
3,818.00
6,126.00
--
Reconciled Depreciation
41,790.00
38,530.00
20,719.00
12,746.00
24,579.00
--
Net Income from Continuing Operation Net Minority Interest
-415,727.00
-376,333.00
-331,468.00
-217,292.00
-169,431.00
--
Total Unusual Items Excluding Goodwill
-11,653.00
-11,394.00
-7,578.00
--
-100,786.00
--
Total Unusual Items
-11,653.00
-11,394.00
-7,578.00
--
-100,786.00
--
Normalized EBITDA
-350,664.00
-314,852.00
-291,844.00
-184,455.00
-44,375.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-4,661.20
-2,392.74
-1,591.38
--
-10,330.57
--
12/31/2019 - 11/8/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CALT Calliditas Therapeutics AB (publ)
38.90
-0.15%
 
MIRM Mirum Pharmaceuticals, Inc.
27.00
+3.05%
 
AVTE Aerovate Therapeutics, Inc.
23.02
+3.46%
 
KALV KalVista Pharmaceuticals, Inc.
12.35
+1.40%
 
OABI OmniAb, Inc.
4.4000
-2.00%
 
ENGN enGene Holdings Inc.
9.90
+13.27%
 
VRDN Viridian Therapeutics, Inc.
12.66
-5.94%
 
VTYX Ventyx Biosciences, Inc.
2.9800
-6.88%
 
ITOS iTeos Therapeutics, Inc.
16.47
+0.92%
 
ZNTL Zentalis Pharmaceuticals, Inc.
9.79
-2.00%